Evidence map›Paper›PMID 24374101›Full record

ReviewBrain research bulletin2014

Can fear extinction be enhanced? A review of pharmacological and behavioral findings.

Paul J Fitzgerald, Jocelyn R Seemann, Stephen Maren

Abstract readReview
In one paragraph

Review in Brain research bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear.The international journal of neuropsychopharmacology · 2022
    Trial
  5. Trial
  6. Augmenting extinction learning with D-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  7. Trial
  8. Review
  9. Article
  10. Science advances · 2025
    Article
  11. Article
  12. Interoception in Fear Learning and Posttraumatic Stress Disorder.Focus (American Psychiatric Publishing) · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Paul J FitzgeraldDepartment of Psychology, Texas A&M University, College Station, TX 77843-4235, United States.
Jocelyn R SeemannInstitute for Neuroscience, Texas A&M University, College Station, TX 77843-4235, United States.
Stephen MarenDepartment of Psychology, Texas A&M University, College Station, TX 77843-4235, United States; Institute for Neuroscience, Texas A&M University, College Station, TX 77843-4235, United States. Electronic address: maren@tamu.edu.
Texas A&M University · US

Funding

Neural Substrates of Contextual Memory in Fear ExtinctionR01MH065961 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAREN, STEPHEN · 2003 to 2025
$7.9M
NIMH NIH HHS R01 MH065961NIMH NIH HHS R01MH065961
6 · The paper itself

Abstract

There is considerable interest, from both a basic and clinical standpoint, in gaining a greater understanding of how pharmaceutical or behavioral manipulations alter fear extinction in animals. Not only does fear extinction in rodents model exposure therapy in humans, where the latter is a cornerstone of behavioral intervention for anxiety disorders such as post-traumatic stress disorder and specific phobias, but also understanding more about extinction provides basic information into learning and memory processes and their underlying circuitry. In this paper, we briefly review three principal approaches that have been used to modulate extinction processes in animals and humans: a purely pharmacological approach, the more widespread approach of combining pharmacology with behavior, and a purely behavioral approach. The pharmacological studies comprise modulation by: brain derived neurotrophic factor (BDNF), d-cycloserine, serotonergic and noradrenergic drugs, neuropeptides, endocannabinoids, glucocorticoids, histone deacetylase (HDAC) inhibitors, and others. These studies strongly suggest that extinction can be modulated by drugs, behavioral interventions, or their combination, although not always in a lasting manner. We suggest that pharmacotherapeutic manipulations provide considerable promise for promoting effective and lasting fear reduction in individuals with anxiety disorders. This article is part of a Special Issue entitled 'Memory enhancement'.

Indexed as

AnimalsConditioning, ClassicalExtinction, PsychologicalFearFluoxetineHumansLevodopaNeurotransmitter AgentsPropranololYohimbineFluoxetineLevodopaNeurotransmitter AgentsPropranololYohimbineContextFluoxetinel-DopaMassed extinctionPropranololYohimbine

Identifiers

PMID24374101
PMCPMC4039692
OpenAlexW2049703399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.